‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Detalles Bibliográficos
Autores principales: Sannareddy, Aishwarya, Reves, Heather, Narasimhan, Madhusudhanan, Jaleta, Kefyalew, Anderson, Julia Marie, Patel, Hetalkumari, Anderson, Larry D., Afrough, Aimaz, Chung, Stephen, Collins, Robert H., Kaur, Gurbakhash, Kumar, Kiran A, Madanat, Yazan F., Vusirikala, Madhuri, Awan, Farrukh T, Muthukumar, Alagar R, Geethakumari, Praveen Ramakrishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2023
Materias:
Poster Session: Infectious Diseases and Cytotoxic T Lymphocytes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899534/
http://dx.doi.org/10.1016/S2666-6367(23)00505-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899534/
http://dx.doi.org/10.1016/S2666-6367(23)00505-5

Ejemplares similares